• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Zimmer Biomet Holdings (ZBH) On Fresh Earnings Momentum And A Fair Value Gap

    Simply Wall St·11/03/2026 14:28:09
    Listen to the news

    Why Zimmer Biomet Holdings (ZBH) Is Back On Investor Radar

    Zimmer Biomet Holdings (ZBH) is drawing fresh attention after reporting 4.8% year over year revenue growth, 33.8% earnings per share growth, manageable net debt to EBITDA of 2.7, and an ongoing annual dividend.

    The share price of Zimmer Biomet Holdings has climbed 10.26% over the past 30 days and 8.14% year to date, yet the 1-year total shareholder return declined 1.49%. This points to improving short-term momentum, while longer-term returns remain under pressure.

    Compare Zimmer Biomet Holdings with other medical technology stocks showing similar momentum in earnings and balance sheet strength using our hand-picked list of solid balance sheet and fundamentals (24 results)

    Bulls point to Zimmer Biomet Holdings’ recent earnings surge and cleaner balance sheet. Bears flag the weak multi year return profile. Which side does the current valuation actually lean toward next?

    Most Popular Narrative: 9.5% Undervalued

    Zimmer Biomet Holdings closed at $97.35 against a narrative fair value of $107.57, so the current share price sits below that framework and puts the focus firmly on whether margin recovery and cost programs can bridge the gap.

    The main factor that has to go right is successful execution of the commercial and cost-efficiency programs, including Project Optima, the global capability center in India, the Costa Rica plant, and integration of acquisitions such as Paragon 28 and iovera, while managing pressure on gross and operating margins.

    The shift of R&D activities to a global capability center in India together with the build out of a manufacturing plant in Costa Rica signals a multi year cost structure reset that could ease manufacturing and engineering expenses, which would be supportive of gross margin and operating margin once initial investments and restructuring charges pass.

    See why 38 investors see Zimmer Biomet Holdings as 10% undervalued.

    Result: Fair Value of $107.57 (UNDERVALUED)

    Still, pricing pressure that Zimmer Biomet Holdings flags at around 80 basis points, along with recent gross and operating margin declines, could quickly challenge the margin recovery story.

    Find out about the key risks to this Zimmer Biomet Holdings narrative.

    Next Steps

    If the mixed tone of Zimmer Biomet Holdings so far leaves you undecided, treat that hesitation as a prompt to move fast and test the numbers yourself. Start by weighing the 3 key rewards and 2 important warning signs.

    Looking for more investment ideas beyond Zimmer Biomet Holdings?

    If Zimmer Biomet Holdings has caught your attention, broaden your opportunity set now and pressure test your portfolio against other ideas before the next move passes you by.